Compile Data Set for Download or QSAR
Report error Found 128 Enz. Inhib. hit(s) with Target = 'Apoptosis regulator Bcl-2 [1-211]'
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571527((rac)-(rac-15)-benzyl-4-chloro-3-ethyl-7-{3-[(6-fl...)
Affinity DataIC50: 1.22E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571495((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 1.32E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571496((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 1.41E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571472((−)-4-chloro-15-cyclopropyl-2,3-dimethyl-7-{...)
Affinity DataIC50: 1.46E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571475((+)-4-chloro-15-cyclopropyl-3-ethyl-7-{3-[(6-fluor...)
Affinity DataIC50: 1.51E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571488((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 1.59E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571469((+)-4-chloro-3-ethyl-2-methyl-7-{3-[(naphthalen-1-...)
Affinity DataIC50: 1.63E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571474((rac)-4-chloro-(15-rac)-cyclopropyl-3-ethyl-7-{3-[...)
Affinity DataIC50: 1.63E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572222(US11447504, Example 79 | (rac)-4-chloro-3-ethyl-7-...)
Affinity DataIC50: 1.70E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571489((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 1.70E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571470((−)-4-chloro-3-ethyl-2-methyl-7-{3-[(naphtha...)
Affinity DataIC50: 1.78E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571477((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 1.81E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571476((−)-4-chloro-15-cyclopropyl-3-ethyl-7-{3-[(6...)
Affinity DataIC50: 1.83E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571463((rac)-4-Chloro-3-ethyl-2-methyl-7-{3-[(naphthalen-...)
Affinity DataIC50: 1.86E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572202(US11478451, Example 086 | (rac)-4-chloro-12,12-dif...)
Affinity DataIC50: 1.88E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572219(US11447504, Example 76 | US11447504, Example 75 | ...)
Affinity DataIC50: 1.90E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572219(US11447504, Example 76 | US11447504, Example 75 | ...)
Affinity DataIC50: 1.90E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571479((−)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthal...)
Affinity DataIC50: 1.93E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM571510((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 1.96E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544459((rac)-(11Z)-4-fluoro-2,3-dimethyl-7-[3-(naphthalen...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544460(US11286263, Example 2 | US11286263, Example 4 | US...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544464((rac)-(11Z)-3-ethyl-4-fluoro-2-methyl-7-[3-(naphth...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544465(US11286263, Example 8 | US11286263, Example 7 | (r...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544470(US11286263, Example 9 | (rac)-(Z)-13-fluoro-10,12-...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544474(US11286263, Example 10 | (rac)-13-fluoro-10,12-dim...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544475(US11286263, Example 11 | (rac)-(Z)-12-ethyl-13-flu...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544476(US11286263, Example 13 | US11286263, Example 12 | ...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544479(US11286263, Example 17 | US11286263, Example 16 | ...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544479(US11286263, Example 17 | US11286263, Example 16 | ...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544482(US11286263, Example 18 | (rac)-13-fluoro-11,12-dim...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544483(US11286263, Example 19 | (rac)-1-(3-((2,3-dihydro-...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544484(US11286263, Example 20 | (rac)-1-(3-(4-chloro-3,5-...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544485((rac)-12-ethyl-13-fluoro-1-(3-((6-fluoronaphthalen...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544485((rac)-12-ethyl-13-fluoro-1-(3-((6-fluoronaphthalen...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544490(US11286263, Example 28 | US11286263, Example 27 | ...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544493(US11286263, Example 30 | (rac)-12-ethyl-13-fluoro-...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544493(US11286263, Example 30 | (rac)-12-ethyl-13-fluoro-...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544495(US11286263, Example 31 | (rac)-1-(3-(4-chloro-3,5-...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544496(US11286263, Example 32 | (rac)-13-fluoro-1-(3-((6-...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544497(US11286263, Example 33 | (rac)-13-fluoro-1-(3-((4-...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544498(US11286263, Example 34 | (rac)-13-fluoro-10,12-dim...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544499(US11286263, Example 35 | (rac)-1-(3-((2,3-dihydro-...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544500(US11286263, Example 36 | (rac)-1-(3-(4-chloro-3,5-...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544501(US11286263, Example 37 | (rac)-12-ethyl-13-fluoro-...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544502(US11286263, Example 40 | (rac)-12-ethyl-13-fluoro-...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544505(US11286263, Example 42 | US11286263, Example 43 | ...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544508(US11286263, Example 44 | (rac)-12-ethyl-13-fluoro-...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544509(US11286263, Example 45 | (rac)-1-(3-((2,3-dihydro-...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544510(US11286263, Example 46 | (rac)-1-(3-(4-chloro-3,5-...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211](Human)
The Broad Institute

US Patent
LigandPNGBDBM544505(US11286263, Example 42 | US11286263, Example 43 | ...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 128 total ) | Next | Last >>
Jump to: